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1A 'prudent use' of antibiotics is always recommended, but is dcult to apply.
French Researcher, Dr. E. Bergogne-Berezin, Participant, Symposium on
Antibiotic Resistance University of Southampton (July 12, 1996)
INTRODUCTION
In the early 1970s, the seemingly banal and nondescript matter of the sub-
therapeutic use of antibiotics in animal feed ignited a contentious debate in
policy circles. For three decades now, this issue has periodically surfaced and
resubmerged, each time provoking a heated but ultimately unresolved debate
regarding the appropriate FDA regulation of the issue. FDA has on several
instances taken initial action to nd itself quickly restrained either by Congress
or by its own ambiguous feelings on the issue. Today, dierent branches of the
Public Health Service, the CDC and the FDA, hold strongly divergent views
on this issue and even the Center for Veterinary Medicine, the Division of the
FDA responsible for regulating the manufacture and distribution of animal feed
additives, appears to house a range of opinion. See infra pp. 13-20.
Subtherapeutic use of antibiotics in animal feed, as opposed to therapeutic
or disease-treating use, enhances eciency of livestock production by promoting
growth. Specically, through an unknown mechanism, an animal on subther-
apeutic doses of antibiotics will, on a lesser quantity of feed, gain an equal
amount of weight as an untreated animal. Animal Legal Defense Fund Boston,
Inc. v. Provimi Veal Corporation, 626 F.Supp. 278, 285-86 (D.Mass. 1986),
a'd without opinion, 802 F.2d 440 (1st Cir. 1987); Telephone Interview with
Rich Carnevale, Vice President of Regulatory, Scientic and International Af-
fairs, Animal Health Institute (January 29, 1998); Telephone Interview with
Dr. Kathy Hollinger, Epidimiologist, Center for Veterinary Medicine, Food and
Drug Administration (January 27, 1998). However, such eciency gains are not
without a cost. Subtherapeutic use of antibiotics poses some unknown level of
risk of negative human health impacts by increasing the rate at which microbial
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2resistance accrues to clincially signicant antibiotics. Some argue that the risk
is too low to justify foregoing the economic benets associated with the sub-
therapuetic regimines, while others argue that the risk is sucient to justify a
ban. An exploration of this debate and of a potential means for better acco-
modating the value conict posed by this debate are the subject of this paper.
Specically, this paper will briey discuss the history of the debate and then
will discuss events leading to a recent reemergence of the issue. Next it will set
forth the terrain of the dispute as it stands currently, and then nally will con-
clude by exploring the viability of labeling as a possible means of accomodating
the divergent values invoked by the issue of subtherapeutic use of antibiotics in
animal feed.
HISTORY
As the history of this issue has been aptly set forth by other authors, Peter
Barton Hutt & Richard A. Merrill, Food and Drug Law, 646-655 (2d ed. 1991),
this paper will only briey summarize key historical developments.
As early as 1970, scientists within the U.S. and Britain began reviewing
the issue of subtherapeutic use of antibiotics in animal feed. Both an FDA
Task Force and a British Task Force, the Swann Committee, concluded that
subtherapeutic use of antibiotics posed a potential hazard to human health and
counseled conservative action. Antibiotic and Sulfonamide Drugs in Animal
Feeds: Proposed Statement of Policy, 37 Fed. Reg. 2444 (1972); Peter Barton
Hutt & Richard A. Merrill, Food and Drug Law, 646-649 (2d ed. 1991). In
response to these ndings, England proceeded to ban the subtherapeutic use
of antibiotics in animal feed. Stuart B. Levy, The Antibiotic Paradox.~ How
Miracle Drugs are Destroying the Miracle 141 (1992). The FDA indicated its
concern about the issue and threatened to revoke existing approvals of uses of
subtherapeutic uses of clinically signicant antibiotics in feeds within two years
unless data to establish their safety and eectiveness under the guidelines of the
Task Force on the Use of Antibiotics in Animal Feeds guidelines were provided.
Antibiotic and Sulfonamide
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3Drugs in Animal Feeds: Proposed Statement of Policy, 37 Fed. Reg. 2444
(1972); Peter Barton Hutt & Richard A. Merrill, Food and Drug Law, 647-649
(2d ed. 1991).
A little over a year after publishing this initial notice, FDA then took a
step away from its earlier pronouncement. The Agency extended the deadlines
before which data was required and set forth language suggesting that the poten-
tial risks posed by subtherapeutic use of antibiotics in feed had to be balanced
against the benets such policy provides. Antibiotic and Sulfonamide Drugs in
the Feed of Animals, 38 Fed. Reg. 9811(1973). After pointing to the economic
benets which accrue from subtherapeutic use of antibiotics, FDA stated that
proof of safety does not require complete certainty of the absolute harmlessness
of a drug, but rather the reasonable certainty in the minds of competent scien-
tists that it is not harmful when balanced against the benets to be obtained
from the drug. Id The agency further stated that withdrawal should be ordered
only once a serious health hazard was demonstrated as it would be chaotic,
and is clearly not feasible, to withdraw approval of all food or drug substances
merely because new questions have arisen, new testing is considered scienti-
cally appropriate, or new studies raise issues that require further exploration.
Id
Winds ofa second policy shift began to rustle in 1977 with the entrance
of new Commissioner, Donald Kennedy. Peter Barton Hutt & Richard A.
Merrill, Food and Drug Law, 650-65 1 (2d ed. 1991); Antibiotics in Animal
Feeds, Center for Veterinary Medicine, Food and Drug Administration Web
Page, http://www.cvm.fda.gov/fdaiinfores/consumer/conl.html FDA gave no-
tice of its intent to propose rules to restrict subtherapeutic use of antibiotics in
animal feeds and specically proposing to ban subtherapeutic use of penicillin
in feed and to restrict use of tetracycline to those situations in which there are
no viable altematives. Peter Barton Hutt & Richard A. Merrill, Food and Drug
Law, 651-652 (2d ed. 1991). According to the FDA, penicillin and the tetra-
cyclines were chosen because of their importance in the treatment of human
disease. Antibiotics in Animal Feeds, Center for Veterinary Medicine, Food and
Drug Administration Web Page, http://www.cvm.fda.gov/fda/infores/
4
4consumer/con I.html.
Once again, however, FDA's move to restrict subtherapeutic antibiotics in
animal feed was aborted. Congress, at the request of farm state legislators
and the livestock and pharmaceutical industries, ordered the FDA to postpone
its rule-making until additional data were gathered and considered. Barbara
O'Brien, Animal Welfare Reform and the Magic Bullet: The Use and Abuse
of Subtherapeutic Doses ofAntibiotics in Livestock, 67 U. Cob. L. Rev. 407,
437 (1996). In retrospect, FDA writes that [t]he 1977 proposed withdrawals
were criticized on the grounds that there was not adequate epidemiological ev-
idence demonstrating that drug-resistant bacteria of animal origin are com-
monly transmitted to humans and cause serious illness. Antibiotics in Animal
Feeds, Center for Veterinary Medicine, Food and Drug Administration Web
Page. http://wsvw.cvm.fda.gov /fda/infores/consumer/conl.html.
In 1978, Congress funded an National Academy of Sciences (NAS) anal-
ysis of the issue. The report produced by the NAS concluded that exist-
ing data had neither proved nor disproved the postulated hazards to human
health from subtherapeutic microbial use in animal feeds and recommended
a set of less expansive but more manageable analyses that could shed light
upon some of the key issues in the debate. Peter Barton Hutt & Richard
A. Merrill, Food and Drug Law, 652 (2d ed. 1991); Antibiotics in Animal
Feeds, Center for Veterinary Medicine, Food and Drug Administration Web
Page, http://www.cvm.fda.gov/fdaIinfores/consumer/conlhtml
Three years later, Congress appropriated funds for an additional comprehen-
sive study of the issue and again the House Appropriations Committee put FDA
on notice that it should not move forward with the proposed withdrawal until
the study was completed. Antibiotics in Animal Feeds, Center for Veterinary
Medicine, Food and Drug Administration Web Page, http://www.cvm.fda.gov
/fdalinfores/consumer/conl.html. FDA selected the Seattle-King Country Dept
of Public Health to conduct the study and received the nal report in August
of 1984. Id Although FDA does not elaborate,
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5the agency was apparently not fully satised with the report, as they describe it
merely by stating that the report has been accepted as having met contractual
obligations. Id
Also in 1984, the Natural Resources Defense Council, Inc. (NRDC), peti-
tioned Health and Human Services (HHS) for immediate suspension of approval
of subtherapeutic use of penicillin and tetracyclines in animal feeds based on
the imminent hazard provision of the Food, Drug and Cosmetic Act, 21 U.S.C.
Sec. 360b(E)(1). Id Based on an analysis of the NRDC's evidence, evidence
gathered at a public hearing and other relevant evidence, HHS Secretary Mar-
garet Heckler denied the NRDC petition in late 1985, stating that an imminent
hazard had not been established. Id.
In early 1989, the second weighty institutional review of the compiled evi-
dence on this issue was released by the Institite of Medicine. Peter Barton Hutt
& Richard A. Merrill, Food and Drug Law, 653 (2d ed. 1991). Like the NAS
report a decade earlier, the IOM report stated that it was unable to nd data
directly implicating the subtherapeutic use of feed antimicrobials in human ill-
ness. Peter Barton Hutt & Richard A. Merrill, Food and DrugLaw, 653 (2d ed.
1991) citing Human Health Risks with the Subtherapeutic Use of Penicillin or
Tetracyclines in Animal Feed (1988). The report further remarked that much
of the available evidence was primarily circumstantial, often ambiguous, and
sometimes conicting. Id According to an industry summary of the report,
[s]cientists concluded that resistance to antibiotics was not solely a function of
usage, but may result from the inevitable process of bacterial evolution. Other
phenomena - including increased human resistance to antibiotics never used in
animals and the prevalence of antibiotic resistance in developing countries where
use of animal antibiotics is uncommon led the experts to conclude that human
antibiotic resistance may be due to a variety of factors other than animal an-
tibiotics. Antibiotics in Animals, The International Food Information Council
Web Page, http://icinfo.health.org/insightIantibiot.htm. The report set forth
a new risk assessment model but stressed that its assumptions were based on an
imcomplete patchwork of data and that the model should be used only to help
guide regulatory policy and should not be interpreted as a specic 'numerical
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6answer' about. .. human health risk. Antibiotics in Animal Feeds, Center for
Veterinary Medicine, Food and Drug Administration Web Page, http://www.cvm.fda.gov/fdaIinfores/consuiner/conlhtml
In the intervening decade, the FDA has continued to monitor this issue.
According to the agency, FDA's Center for Veterinary Medicine has since the
mid-80s completed an extensive literature review pertaining to all of the issues
of science and health and has summarized scientic data from all completed
contractual studies and articles printed in the scientic literature. Id The FDA
position has been characterized by watchful concern but basic endorsement of
standing policy. The FDA web page on the issue acknowledges existence of a
risk, stating that [b]ecause these uses promote the development of drug resistant
bacteria in animals, and routes for movement of these resistant bacteria to man
are available, the Center believes that drug resistance in the bacteria associated
with food animals can aect the proportion of drug resistant bacteria that cause
human diseases. Therefore, the potential exists for compromise of drug therapy
in animals and in humans. Id On the whole however, the agency nds the risk
to be adequately balanced by countervailing benets. In the words of CVM
Director, Stephen Sundlof, [w]hile there are some risks associated with using
antibiotics in animal agriculture, if managed properly, the benets outweigh the
risks. Antibiotics in Animals, The International Food Information Council Web
Page, http://icinfo.health.org/insight/antibiot.htm.
RECENT EVENTS REIGNITE THE DOMESTIC DEBATE
After a relatively sleepy period, recent events have brought a resurgence of
interest and activity on the issue of subtherapeutic use of antibiotics. Events in
the second half of 1997, decisive but controversial international action and do-
mestic controversy over uoroquinolones, gave rise to increased reection both
within and outside of FDA about the subtherapeutic use of antibiotics in ani-
mals. Telephone Interview with Rich Carnevale, Vice President of Regulatory,
Scientic and International Aairs, Animal Health Institute (January 29, 1998).
Telephone Interview with Fred Angulo,
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7Epidimiologist, Foodborne and Diarrheal Diseases Branch, Centers for Disease
Prevention and Control (January 27, 1998).
INTERNATIONAL EVENTS
On October 17, 1997, the World Health Organization adopted a formal policy
of opposition to the use of subtherapeutic levels of antibiotics in feed following a
four day meeting of 70 international experts. Antibiotic Use in Food-Producing
Animals Must Be Curtailed to Prevent Increased Resistance in Humans, World
Health Organization Web Page, http://wwwhq.who.or.jp/press/1997/pr97-73.html.
WHO stated that antibiotic use in food-producing animals must be curtailed to
prevent increased resistance in humans. Id. [A]ntimicrobials are vital medicines
to treat human infections but their eectiveness is threatened by overuse and
inappropriate use which contributes to the growing resistance of bacteria. Id
In particular, the WHO stated that [r]esistant strains of.. . bacteria that cause
disease in humans have been transferred from animals to humans and (have
been) shown to have consequences for human health and pointed to existence
of [d]irect evidence that antibiotic use in food-producing animals results in re-
sistant. .. infections in humans. Id
In addition to this policy announcement by the WHO, other signicant in-
ternational action also occurred. The Swedish, who have had a domestic ban on
subtherapeutic use of antibiotics in animal feed since 1986, Swedish Livestock
Antibiotic Use Down Sharply, Agra Europe, Nov. 8, 1996, launched a campaign
to convince the E.U. of the wisdom of their position. Under the terms of its
accession to the E.U., Sweden was granted a window of time in which it could
retain its ban. Swedes Push for Cuts in Antibiotic Use, Agra Europe, Nov 14,
1997. That window, however, is fast elapsing and Sweden does not wish to have
to relinquish their ban. Id. In the words of the Swedish Agriculture Minister,
We would regard it as completely out of the question and unacceptable if we
were required to alter our legislation in this time of growing awareness of the
problem of antibiotics resistance.' Id As part of its
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risks of increased microbial resistance were more signicant than the benets of
growth promotion. Id. The report, produced by the Swedish Commission on
Antimicrobial Feed Additives (AFAs) stated that 'the risk of increased resistance
associated with the general use of antibacterials as feed additives are far from
negligible and the potential consequences are serious for both animal and human
health.' Id
A third signicant action on the international front was the banning of the
subtherapeutic use of the antibiotic avoparcin by the E.U. in response to current
resistance concerns. Id
Because of the potential relevance to these international experiences to our
domestic debate, it is important to note that these international actions were
based not on uncontroversial data but on a precautionary ethic. The WHO
proceedings have been criticized as being one-sided and overly-dominated by
those with an exclusive public health orientation. Telephone Interview with
Sarah Lister, Congressional Aide, Senate Agriculture Committee Minority Sta
(January 28, 1998). This critique is buttressed by the fact that the WHO
statements themselves treat the economic considerations involved in a relatively
dismissive and supercial manner. A decrease in use of antibiotics as growth
promoters does not need to entail reduced productivity in animals and thereby
economic losses to the food producer nor increased prices for (the) consumer. It
will also not necessarily result in the increased use of other drugs in the place of
antibiotics.. . Research on alternative methods to improve animal growth and
feed eciency was recommended. Antibiotic Use in Food-Producing Animals
Must Be Curtailed to Prevent Increased Resistance in Humans, World Health
Organization Web Page, http://wwwhq.who.or.jp /press/1 997/pr97-73.html.
The action of the E.U. in banning avoparcin was also not without contro-
versy. Leading up the the banning of avoparcin, UK made arguments similar
to those employed in the U.S. The UK has argued that the ban on avoparcin,
which is produced in the UK by Roche Pharmaceuticals, is not based on sound
scientic evidence. . The UK is concerned that banning substances by referring
to the
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ect...could
establish an unwelcome precedent.. . EU Ban on Avoparcin Blocked; UK Com-
missioners Block Ban on Feed Additive, Agra Europe, Jan 24, 1997. The sci-
entic basis for the decision was also called into question by an independent
scientic panel, the Scientic Commission of Animal Nutrition. J. Bates, Re-
view:
Epidimiology of Vancomycin-Resistant Enterococci in the Communityand the
Relevance of Farm Animals to Human Infection, 37 Journal of Hospital Infection
89, 96-97 (1997). The Commission was asked to make an objective decision
on behalf of the EU in answer to the question: 'Does the use of avoparcin
constitute a danger to human health?' Althrough not unanimous, it was the
committee's nding that there was at present insucient evidence. Id In spite
of this nding of insucient evidence, the E.U. proceeded to impose a ban on
the use of avoparcin in feed. Id. The decision, which has been described as
being largely due to public pressure, is subject to review in two years. Id
FLUOROQUINOLONE DEBATE
The second factor causing a reawakening of the domestic debate over sub-
therapeutic use of antibiotics in feed is the current debate over uorquinolone
policy. Telephone Interview with Rich Carnevale, Vice President of Regula-
tory, Scientic and International Aairs, Animal Health Institute (January 29,
1998); Telephone Interview with Fred Angulo, Epidimiologist, Foodborne and
Diarrheal Diseases Branch, Centers for Disease Prevention and Control (January
27, 1998); Telephone Interview with Sarah Lister, Congressional Aide, Senate
Agriculture Committee Minority Sta (January 28, 1998). Fluoroquinolones
are signicant because they are our current last line of defense against some
bacteria. Telephone Interview with Fred Angulo, Epidimiologist, Foodborne
and Diarrheal Diseases Branch, Centers for Disease Prevention and Control
(January 27, 1998); Telephone Interview with Sarah Lister, Congressional Aide,
Senate Agriculture Committee Minority Sta (January 28, 1998). Therapeutic
use of uorquinolones in poultry was approved by the FDA in 1995 and Bayer,
the manufacturer of these
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10antibiotics, has recently sought FDA approval for use of 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ditional livestock. Marian Burros, Health Concerns Mounting Over Bacteria in
Chickens, New York Times, Oct. 20, 1997 at Al. This request for expansion
became quite controversial this fall when the NYT reported that campylobacter
bacteria, a bacteria found on between 70 to 90% of all chickens, was found to be
showing resistance to the uoroquinolone class of antibiotics. Id Since the ap-
proval of the use of uoroquinolones in poultry in 1995, the Minnesota Health
Department had observed increased levels of drug resistant campylobacter in
humans. Id According to the Department's random sampling in supermarkets,
79% of the chickens sampled were infected with campylobacter and of these,
20% had resistant strains. Of turkeys, 58% had campylobacter and 89% had
resistant strains. Id. The data are being submitted to a scientc journal for
publication. Id Similar results have been observed in a number of other coun-
tries. Id; Antibiotic Use in Food-Producing Animals Must Be Curtailed to Pre-
vent Increased Resistance in Humans, World Health Organization Web Page,
http://wwwhq.who.or.jp/press/ l997/pr97-73.htm I.
Although the uoroquinolone debate is about the appropriateness of thera-
peutic use of uoroquinolones, the debate is raising the question of the appropri-
ateness of subtherapeutic use of antibiotics also. Telephone Interview with Fred
Angulo, Epidimiologist, Foodborne and Diarrheal Diseases Branch, Centers for
Disease Prevention and Control (January 27, 1998). The reason is twofold.
First, in the eyes of those who counsel conservative use of antibiotics, there is in
practice a ne line between therapeutic use and subtherapeutic use. Telephone
Interview with Kathy Hollinger, Epidimiologist, Center for Veterinary Medicine,
FDA (January 27, 1998); Telephone Interview with Fred Angulo, Epidimiolo-
gist, Foodborne and Diarrheal Diseases Branch, Centers for Disease Prevention
and Control (January 27, 1998). According to Hollinger, Right now there are a
lot of drugs being abused.. . Most drugs we put out on the market are abused
in some fashion. Telephone Interview with Kathy Hollinger, Epidimiologist,
Center for Veterinary Medicine, FDA (January 27, 1998). Angulo and
11
11Lister point out that the way antibiotics are applied therapeutically illustrates
the ne line dividing the two categories. Telephone Interview with Kathy
Hollinger, Epidimiologist, Center for Veterinary Medicine, FDA (January 27,
1998); Telephone Interview with Fred Angulo, Epidimiologist, Foodborne and
Diarrheal Diseases Branch, Centers for Disease Prevention and Control (January
27, 1998). Fluorquinolones are apparently applied in drinking water. Telephone
Interview with Sarah Lister, Congressional Aide, Senate Agriculture Commit-
tee Minority Sta (January 28, 1998); Telephone Interview with Fred Angulo,
Epidimiologist, Foodborne and Diarrheal Diseases Branch, Centers for Disease
Prevention and Control (January 27, 1998). Secondly, because uoroquinolones
are such important human clinical drugs, the debate highlights the whole issue
of trade-os between the benets of eciencies of livestock production and the
potential risks to human health.
The future implications of these current events are dicult to determine.
According to some commentators, the issue of antibiotic use is a very hot issue
for the FDA right now, Telephone Interview with Fred Angulo, Epidimiolo-
gist, Foodborne and Diarrheal Diseases Branch, Centers for Disease Prevention
and Control (January 27, 1998), causing the agency to do some soul-searching.
Amanda Spake et al., 0 is for Outbreaks, U.S. News and World Report, Novem-
ber 24, 1997. However, this is certainly not the rst time that predictions of
imminent change have been made with regard to this issue. Barbara O'Brien,
Animal Welfare Reform and the Magic Bullet: The Use andAbuse of Subther-
apeutic Doses ofAntibiotics in Livestock, 67 U. Cob. L. Rev. 407, 438 (1996).
Others perceive the present as a periodic resurfacing of the same old issues.
Telephone Interview with Jean Cooper, Veterinary Medical Ocer, Center for
Veterinary Medicine, FDA (January 28, 1998). Cooper reports that the issue
comes and goes and that she doesn't see this time as dierent. Id
One means of attempting to determine how close these issues are to resolu-
tion is to examine the views of key players. The following section lays forth the
basic terrain of the current debate.
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12PERSPECTIVES: THE EPIDIMIOLOGIST VS. THE RISK ASSESSER
This debate is centrally staked out by two camps1, those with an epidimio-
logical perspective and those with a risk assessment perspective. The following
pages will lay out the arguments of both paradigms, citing signicant players in
the debate.
THE EPIDIMIOLOGISTS
The epidimiological perspective regards human health as the primary con-
sideration in this debate. Examples of thoseholding this perspective include the
CDC, the WHO and many physicians.
Because they privilege human health concerns, those with the epidimiologi-
cal perspective tend to believe that any use which detracts from the potency of
antibiotics for human medicine is highly suspect. In the words of Fred Angulo of
the Centers for Disease Control and Prevention, CDC believes that antibiotics
should be used prudently. Prudence is dened as use that maximizes the ther-
apeutic eect and minimizes the emergence of resistance. Telephone Interview
with Fred Angulo. Epidimiologist, Foodborne and Diarrheal Diseases Branch,
Centers for Disease Prevention and Control (January 27, 1998). Since with an-
tibiotics, the more you use them the faster you lose them, Patrick Wall, Chief
of Gastrointestinal Disease, Public Health Service Laboratory, London cited in
Amanda Spake et al., 0 is for Outbreaks, U.S. News and World Report, Novem-
ber 24, 1997, they see widespread and nonessential animal use as unacceptably
eating away antibiotic potency that may mean fewer treatment options in hu-
man medicine. To give a sense of the magnitude of increased loss of resistance
due to what they view as nonessential animal use, they point to the size of the
market. Together,
The animal rights/animal welfare perspective constitutes a third basic posi-
tion in the debate. This perspective more fundamentally critiques the eency-
driven modem livestock production systems. As such a critique is beyond the
scope of this paper, it will not be addressed here. For more information on this
perspective, see Animal Welfare Reform and the Magic Bullet: The Use and
Abuse of Subtherapeutic Doses of Antibiotics in Livestock, 67 UColo. L.Rev.
407 (1996) (arguing that the subtherapeutic antibiotics issue is a potential means
of aecting broader issues of animal well-being).
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13subtherapeutic and therapeutic antibiotics used in farm animals equal half of
the global antibiotic market. Vincent Perreten, et al., Antibiotic Resistance
Spread in Food, 389 Nature 801 (1997). Of this market, the proportionate
breakdown of subtherapeutic versus therapeutic use is dicult to pinpoint, but
the subtherapeutic use is unquestionably signicant. A well-known crusader for
protection of our antibiotic reserves, Dr. Stuart Levy, has put the subthera-
peutic gure at around 80%. Stuart B. Levy, The Antibiotic Paradox: How
Miracle Drugs are Destroying the Miracle 140 (1992). A more conservative es-
timate might put the gure closer to 35%, the amount by which Sweden's total
use of antibiotics in animals decreased after Sweden banned the subtherapeu-
tic use of antibtiotics. Swedish Livestock Antibiotic Use Down Sharply, Agra
Europe, Nov 8, 1996. Whatever the exact statistics, given the importance of
human health considerations, the view the collective data on risks presented
by subtherapeutic use of antibiotics as presently sucient grounds for a ban
on the practice. Antibiotic Use in Food-Producing Animals Must Be Curtailed
to Prevent Increased Resistance in Humans, World Health Organization Web
Page, http://wwwhq.who.or.jp/press/1997/pr97-73.html. In the words of Con-
gressional Aide Lister, The CDC and people who deal with public health see a
lot of this stu as a no brainer. Telephone Interview with Sarah Lister, Congres-
sional Aide, Senate Agriculture Committee Minority Sta (January 28, 1998).
Those of the epidimiological perspective tend to view the FDA regulatory
approach as inadequate, calling it worrysome. Telephone Interview with Fred
Angulo, Epidimiologist, Foodborne and Diarrheal Diseases Branch, Centers for
Disease Prevention and Control (January 27, 1998). The FDA approval process
is not adequate to address the current issue... The legal mechanism doesn't
take into account why society needs a drug... And if a drug is approved, a legal
battle to get it o the market could take up to 10 years, at which point the
utility of the drug has decreased to close to zero. That regulatory framework
causes us in public health to be concerned. Id.
Those within the epidimiological paradigm also recommend prompt action
to restrict
14
14subtherapeutic use of penicillin and tetracycline, disagreeing with the claims
of some that such restrictions would be too late to be eective. Telephone In-
terview with Kathy Hollinger, Epidimiologist, Center for Veterinary Medicine,
FDA (January 27, 1998); Telephone Interview with Fred Angulo, Epidimiolo-
gist, Foodborne and Diarrheal Diseases Branch, Centers for Disease Prevention
and Control (January 27, 1998). Describing the policy of the CDC, Angulo
states [w]e support the WHO policy which says that use of certain classes of
antibiotics should be terminated. We call for the termination of the subthera-
peutic use of penicillin and tetracycline. Telephone Interview with Fred Angulo,
Epidimiologist, Foodborne and Diarrheal Diseases Branch, Centers for Disease
Prevention and Control (January 27, 1998). Both Angulo and Hollinger point to
the resurgence in resistance experienced by Sweden after it reduced its antibiotic
use in agriculture. Telephone Interview with Kathy Hollinger, Epidimiologist,
Center for Veterinary Medicine, FDA (January 27, 1998); Telephone Interview
with Fred Angulo, Epidimiologist, Foodborne and Diarrheal Diseases Branch,
Centers for Disease Prevention and Control (January 27, 1998).
Believing strongly in precaution where public health is concerned, epidimiol-
ogists also tend to believe that uroquinolones, as our current last line of defense,
should not be approved for use in animals even for restricted therapuetic use.
Pointing to the ne line between subtherapeutic and therapeutic use, Angulo
states that, We need to evaluate current approval of oroquinolones for thera-
peutic use for prudence. Telephone Interview with Fred Angulo, Epidimiologist,
Foodborne and Diarrheal Diseases Branch, Centers for Disease Prevention and
Control (January 27, 1998). According to Patty Leiderman of the Center for
Science in the Public Interest, the current need to resort to uroquinolones in
animal treatment results from the careless use of previous antibiotics and thus
doesn't instill condence that uoroquinolines will be used responsibly. Tele-
phone Conversation with Patty Leiderman, Center for Science in the Public
Interest (January 27, 1998). Lister points out that in light of the recent Min-
nesota Health Department report regarding campylobacter resistance to uoro-
quinolones
15
15and the fact that such resistance developed so quickly (since 1995 approval of
uoroquinolones in poultry), we should be reticent with regard to future uo-
roquinolone approvals. Telephone Interview with Sarah Lister, Congressional
Aide, Senate Agriculture Committee Minority Sta (January 28, 1998). If we
are going to lose this antibiotic 3 yrs after putting it out there, it is not worth
it. Id.
At essence, the theoretical underpinning of the epidimiological perspective
in the subtherapeutic use of antibiotic debate is a variant of the precautionary
principle. According to Professor Cross, author of an article discussing and
critiquing the precautionary principle, the rst formulation of the precautionary
principle was set forth by Talbot Page in 1978. Frank B. Cross, Paradoxical
Perils of the Precautionary Principle, 53 Wash. & Lee L. Rev. 851, 852 (1996).
In Cross's words, in the Page paradigm a false negative could cost lives, while
a false positive, such as banning a truly harmless chemical, would have only
economic consequences and probably minor ones at that. Given the asymmetry
in the consequences of error, Page urged that we error on the side of preventing
false negatives at the expense of some false positives. Id This higher valuing
of human health and life over potential economic consequences even at the
expense of potential false positives is the basic underpinning of the general
epidimiological disapproval of the subtherapeutic use of antibiotics in animal
feed.
THE RISK REGULATORS
The alternate perspective in this debate is that of the risk regulator. Key
proponents of this view include the FDA and members of industry. In this
perspective, public health protection is a very important consideration but has
to be balanced against other factors in the equation. Thus, consideration of
what is forgone by imposing a given level of regulation as is quantication of
the level of risk posed.
The risk regulator perspective either explicitly or implicitly considers bene-
ts derived from tolerating current levels of risk. In the already quoted words
of the present CVM Director, While there
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16are some risks associated with using antibiotics in animal agriculture, if managed
properly, the benets outweigh the risks. Antibiotics in Animals, The Interna-
tional Food Information Council Web Page, http://icinfo.health.org/insight/antibiot.htm.
While debate participants state that the exact levels of economic benet are dif-
cult to quantify, Rich Camevale, Vice President of Regulatory, Scientic and
International Aairs, Animal Health Institute (January 29, 1998), one estimate
is that antibiotics allow a 2-3% gain in feed eciency over what would occur
without antibiotics. Telephone Interview with Jean Cooper, Veterinary Medical
Ocer, Center for Veterinary Medicine, FDA (January 28, 1998). Although
this may sound insignicant, even slight eciency gains translated over large
numbers of animals become extremely important. Rich Carnevale, Vice Presi-
dent of Regulatory, Scientic and International Aairs, Animal Health Institute
(January 29, 1998). In addition, if the practice were not resulting in eciency
gains, one would assume that producers would not purchase the antibiotics. Pro-
ducers wouldn't do it unless it was protable. Telephone Interview with Jean
Cooper, Veterinary Medical Ocer, Center for Veterinary Medicine, FDA (Jan-
uary 28, 1998). Specic statistics on the benet to consumers of this eciency
gain are elusive. Rich Carnevale, Vice President of Regulatory, Scientic and
International Aairs, Animal Health Institute (January 29, 1998). Nonetheless,
based on global statistics, it is clear that U.S. consumers pay less for food than
individuals in other countries. U.S. consumers have beneted from American
food-production capabilities. Americans spend proportionately less on food,
about 11 percent of their income, than do most residents of other parts of the
world. In Europe, consumers spend about 14 percent of their income on food; in
Japan, 21 percent; in China, about 48 percent. The percentage of income Amer-
icans spend on food has dropped by 50 percent since the turn of the century.
Backgrounder- Agriculture and Food Production, International Food Informa-
tion Council Web Page, http://icinfo.health.org/backgroundIbkgr12.htm.
Because countervailing benets are tangible to them, risk regulators are
unconvinced by vague assertions of potential scientic risks. According to Lister,
public health assumes reasonable inferences
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17if no one has disproven them.. . But risk assessment says prove it. Telephone
Interview with Sarah Lister, Congressional Aide, Senate Agriculture Commit-
tee Minority Sta (January 28, 1998). In Carnevale's words, millions have been
spent looking at the issue: how big is the risk? The bottom line is that no
one has been able to determine that the frequency of transmission is signicant.
Yes, it can happen but what is the impact? It is very dicult to conclude scien-
tically that there is a real risk. Rich Carnevale, Vice President of Regulatory,
Scientic and International Aairs, Animal Health Institute (January 29, 1998).
Cooper of FDA agrees and emphasizes that FDA has a dierent mandate than
CDC. Telephone Interview with Jean Cooper, Veterinary Medical Ocer, Cen-
ter for Veterinary Medicine, FDA (January 28, 1998). She says that no one has
denitively proven that resistance to antibiotics in an animal is going to result
in impact on human health. The question is how often resistance is spread from
a treated animal to a human pathogen. CDC says it is often enough to cause
a problem but we have no proof. Id FDA has to strike the balance between
potentially harming a few vs. potentially raising the cost of food. There are
two sides of the debate: one says we may have a problem and the other says we
have a problem. To the regulator, outliers on bell curve don't matter where as
to the epidimiologist, every incident is an issue... FDA cares about risk assess-
ment, about the general eect on the general public. We aren't guaranteeing
zero risk. A lot of people don't understand that about how FDA works. We try
to minimize the risk. There is no way to eliminate it. On this issue, we would
take action if had more data, especially data on frequency. We have no good
data, only soft surveillance data. Id.
Risk assessors acknowledge that through increased use we are likely acceler-
ating the rate at which resistance accrues, but say that through careful controls
we can attain the benets of use while limiting loss of resistance. If you are using
an antibiotic, you are going to get some resistance to it at some point. It is going
to happen. The only question is the pace. You want to control how much occurs
and make sure you don't create resistance unneccessarily. Telephone Interview
with Rich Carnevale,
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18Vice President of Regulatory, Scientic and International Aairs, Animal Health
Institute (January 29, 1998). To that end, risk assessors argue that the current
system of case by case approval is adequate. We advocate carefully controlled
use rather than banning. Johan Vanhemelrijk, Secretary General of the Euro-
pean Animal Health Federation (FEDESA) agrees. Swedes Push for Cuts in
Antibiotic Use, Agra Europe, Nov. 14, 1997. 'We support a system of indi-
vidual risk assessment based on scientic evaluation of the criteria of quality,
safety and ecacy.' Id In addition, Carnevale points out that these products are
highly regulated. Telephone Interview with Rich Carnevale, Vice President of
Regulatory, Scientic and International Aairs, Animal Health Institute (Jan-
uary 29, 1998). FDA species the conditions for use of each drug in detail. Id.
In addition to these regulatory controls, risk regulators point out that there are
additional checks on antibiotic use because producers count on the eectiveness
of antibiotics to treat sick animals and because these drugs are costly. Id
As to the issue of penicillin and tetracycline, risk regulators tend to argue
that use of these drugs has decreased on its own and that many of the prod-
ucts used commonly in animals are not useful in human medicine. Telephone
Interview with Rich Carnevale, Vice President of Regulatory, Scientic and
International Aairs, Animal Health Institute (January 29, 1998); Telephone
Interview with Jean Cooper, Veterinary Medical Ocer, Center for Veterinary
Medicine, FDA (January 28, 1998). As to the ourquinolones, the risk regula-
tor perspective once again favors controlled use over banning. They report that
an FDA advisory committee studied the issue three years ago and reached the
conclusion that there was a need for treatment with uorquinolones and that
it should be allowed under limited, veterinarian controlled therapuetic circum-
stances subject to post approval monitoring. Telephone Interview with Rich
Carnevale, Vice President of Regulatory, Scientic and International Aairs,
Animal Health Institute (January 29, 1998). Risk regulators tend to view that
policy as the appropriate balancing of the factors involved. Id. In response
to the NYT report that 20% of campylobacter chickens randomly sampled in
Minnesota were uoroquinolone resistant, the risk regulator perspective
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19again questions the data and the implied mechanism of action. National Broiler
Council representative Kenneth May stated, We don't treat anything like 20% of
chickens with uorquinolones. Lisa Zimmerman, Campylobacter News Not Af-
fecting Sales; Bacteria Commonly Present In Raw Chicken, Supermarket News,
Nov. 3, 1997. National Broiler Council representative Roenigk, agreed, stating
Less than 1/10 of 1% of chickens get treated with uorquinolone. .. uoro-
quinolone is 25 times more expensive [than other antibiotics]. Id Dean Cliver,
a professor of food safety at U.C. Davis said that he was not worried about
uoroquinolone resistant campylobacter in humans because 'antibiotics are not
recommended for treatment of campylobacter [in humans]. Id. Cliver said that
the more important issue was people learning to handle raw chicken. Id
The theoretical underpinning of the risk regulator perspective is also set
forth by Professor Cross. Frank B. Cross, Paradoxical Perils of the Precaution-
ary Principle, 53 Wash. & Lee L. Rev. 851, 852 (1996). Cross critiques the
precautionary principle by stating, among other things, that it skews prioritiza-
tion of government eorts to reduce risk. The consequence is less risk reduction
than would otherwise occur. Id. at 86 1-2. He proposes an alternative principle
which is grounded in the limitations and uncertainties of scientic knowledge.
While these limitations are undeniable, they do not call for an articial decision
rule that ignores the science, such as the precautionary principle. Rather, poli-
cymakers should confront the scientic uncertainty and act prudently in accord
with the best possible scientic understanding. This approach may sometimes
call for precaution, but only after considering the potentially substantial risks
attendant to precaution. The proposed policy might itself be considered a form
of the precautionary principle, though in vastly expanded form, with better
recognition of the full consequences of regulatory action. Id.
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20IN THE FACE OF THIS ENTRENCHED VALUES-BASED DISAGREEMENT:
SHOULD WE ALLOW THE CONSUMER TO CHOOSE?
The above sections set forth the two basic sides of this debate. Barring
some catastrophic event, the future of this debate will likely bring continued
ghting and thus continued supremacy of the risk regulator approach, despite
existence of signicant dissension. Given the current lack of consensus about
the values-based dilemma presented by subtherapeutic use of antibiotics, the
possibility of using a labeling mechanism to accomodate broader levels of choice
and expression suggests itself. A labeling scheme would allow consumers to
express their views on this values debate through the market, thus diminishing
the hegemonic importance of the particular position adopted by the regulatory
scheme.
In considering the labeling option, three questions need to be answered: 1)
Would such a labeling scheme be legal? 2) Is such a labeling scheme desirable?
and 3) Could it work?
LEGAL CONTEXT
Recent case law and FDA guidance indicate that non-misleading voluntary
labeling by producers is permissible.
The Second Circuit recently declared unconstitutional a Vermont law re-
quiring rBST (recombinant Bovine Somatotropin) labeling of dairy products,
nding that Vermont had failed to assert a substantial state interest to justify
its intrusion on constitionally protected rights. International Dairy Foods Ass
'12 v. Amestoy, 92 F.3d 67 (2nd Cir. 1996). The court left open the question of
whether mandatory labeling could be acceptable in a case in which a substantial
state interest was demonstrated. Absent.., some indication that this information
bears on a reasonable concern for human health or safety or some other su-
ciently substantial government concern, the manufactures cannot be compelled
to disclose it. Instead, those consumers interested in such information should
exercise the power of their purses by buying products from manufacturers who
voluntarily reveal it. Id at 74. Future decisions
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21will help to resolve the balance to be struck regarding mandatory labeling, but
in the meantime, it is safe to assume based on International Dairy Foods that
voluntary labeling is permissible.
In addition, the FDA has issued potentially relevant guidance on the content
of labels in the rBST context. Fredrick Degnan, The Food Label and the Right-to-
Know, 52 Food & Drug L. J. 49, 55-59 (1997). Such guidance emphasize(s) that
if voluntary labeling is to be employed, misleading implications must be avoided
and that the information presented must appear in its proper context. Id. at
56. The agency has cautioned that even truthful information could mislead
consumers. Id. In specic terms, [t]he interim guidance suggests that whenever
a dairy product carries a label that reads from cows not treated with rBST, the
label should also include the disclaimer that [n]o signicant dierence has been
shown between milk derived from rBST-treated and non-rBST treated cows.
Terence J. Centner & Kyle W. Lathrop, Labeling rBST-Derived Milk Products:
State Responses to Federal Law, 45 Kansas L. Rev. 511, 523 (1997). While the
presence of a legitimate scientic dispute may distinguish the subtherapeutic
antibiotic case from the rBST case, even if the rBST guidance is applicable
in its entirety to the subtherapeutic antibiotics case, it should not present a
problem with thoughtful drafting.
To summarize, a voluntary, non-misleading labeling program for animal
products raised without subtherapeutic use of antibiotics should not encounter
legal stumbling blocks.
IS LABELING DESIRABLE [N A CASE SUCH AS THIS?
Two categories of argument suggest the desirability of labeling in the sub-
therapeutic antibiotic case: "information economics" arguments and conscious-
ness raising" arguments.
Several powerful justications for labeling are provided by the information
economics approach. First, informational approaches to regulation enhance per-
sonal liberty by increasing the power of the individual to make free choices. ..
Second, informational approaches increase economic eciency by
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22providing information that consumers want, but because of some market failure,
do not have. Third, informational approaches enhance democracy because they
promote citizen participation in and debate over risk management. Michael
Barsa, California 's Proposition 65 & the Limits of Information Economics,
49 Stanford L. Rev. 1223, 1226-7 (1997) citing Cass. R. Sunstein, Informing
America: Risk, Disclosure and the First Amendment, 20 Fla. St. U. L. Rev.
653, 655-58 (1993).
Second, labeling in the context of this debate may also provide the additional
benet of consciousness raising set forth by Barsa in his discussion of California's
Proposition 65. Michael Barsa, Cal~fornia 's Proposition 65 & the Limits of
Information Economics, 49 Stanford L. Rev. 1223, 1238-1247 (1997). While
on its face Propositon 65 seems to be all about informing consumers, it also
supplies powerful incentives to manufacturers to become informed about and
possibly reduce the carcinogens and teratogens in their products. Id at 1239.
Barsa reports that Proposition 65 has encouraged industry to reduce the level
of toxins or to keep toxins out of the market entirely to escape the warning
requiremnts. Id at 1240. Although weaker within a voluntary labeling system,
a consciousness raising eect would likely still occur in this case to some degree
either because of pruducer desire to take advantage of a potentially signicant
market or possibly, in the future, to escape the stigma of not having a label.
The incentive to alter production processes could become signicant in time if
the organic foods market is any indicator of the potential for market expansion.
Since 1990, organic sales have skyrocketed at the rate of twenty percent per
year, propelling organic food to the status of a legitimate food niche with annual
sales between $2.9 and $3.3 billion. Kenneth C. Amaditz, The Organic Foods
Production Act of 1990 and its Impending Regulations: A Big Zero for Organic
Food?, 52 Food & Drug L. J. 537 (1997). The French experience also documents
the potential of a signicant market. The French have a system of meat labeling
which occupies a substantial market segment. There are no fewer than 5300
Label Rouge poultry farmers in France, and they represent one third of the
poultry sold in France. This is true even though the price premium for such
products is
23
23200-300%. Neil Murray, Red Means Go; Free Range Chicken Market in the UK,
Frozen and Chilled Foods, August, 1997. Given this potential for future impact
on production processes, the consciousness raising justication further supports
the desirability of labeling in the subtherapeutic antibiotic context.
COULD IT WORK?
A voluntary labeling approach would appear to lead to the predicted bene-
ts set forth by the information economics paradigm above. First, by providing
the information necessary to distinguish products on the basis of subtherapeu-
tic antibiotic use, a labeling approach will supply an incentive to raise animals
without use of subtherapeutic antibiotics. This, in turn, will provide consumers
a choice that was not present before initiation of the labeling scheme, enabling
them to weigh the considerations involved on either side of the debate. Second,
because such labeling would provide at least some consumers access to informa-
tion that they deem relevant to their purchasing decisions but that they did not
formerly have, a labeling approach would thus also increase market eciency
by reducing an information imperfection in the market. Third, labeling would
also be likely to enhance democracy by informing consumers of the existence
of this debate and by tabulating their votes on the matter through the market
mechanism.
Critics would point to a number of potential downsides to the labeling ap-
proach. First, they would argue that it is actually not desirable to make risk
regulation decisions more democratic given the reality of irrational public risk
perception. Second, critics would question whether the public has the capacity
to really understand a warning on the subtherapeutic antibiotic issue. They
would point out that the debate is somewhat complex and technical and the
language confusing. Third, critics would also point to the incompleteness of
the information provided by such a labeling approach and ask why this issue is
being privileged above other important issues. They would question whether it
makes sense to begin the labeling enterprise given the impossibility of providing
perfect labeling on all issues. Fourth,
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24critics would argue that if we start labeling to allow people to express their val-
ues, this will lead to an ever-expanding quantity of labels that will ultimately
completely overwhelm consumers, rendering the entire labeling enterprise mean-
ingless. Fifth, critics would argue that it is strange to have a labeling system in
a premium is paid not to avoid a potential personal risk but a potential public
risk.
Many of these concerns are surmountable. With respect to the rst issue,
the question of the desirability of democracy in regulation, the pro-labeling
perspective would respond that popular input on regulatory decisions actu-
ally is desirable when scientic consensus is lacking and values questions are
paramount.
As to the question of whether consumers can grasp the issues at stake, the
pro-labeling perspective believes strongly that most consumers will denitely
be able to comprehend this issue. Most individuals with access to mainstream
media of any sort will already have signicant grasp of the issues involved and
will relatively quickly be able to absorb additional information and develop a
personal opinion on the matter. Even in the worst case scenario, however, if
only some individuals were able to understand and process the information, even
that incremental increase in informed choice would be an enhancement over no
choice at all.
Third, the labeling proponent would acknowledge both the incompleteness
of the labeling exercise and its privileging of some issues over others. However,
given that perfect decision-making is an impossibility, the labeling advocate
would argue that the relevant question should be whether a given label has ren-
dered decision-making less imperfect than it otherwise would have been. The
labeling advocate believes that we should look for improvement not perfection.
True, the information is still incomplete but if it is less incomplete than it oth-
erwise would have been, the label has incrementally diminished the information
imperfections of the market.
Fourth, the labeling advocate disputes the argument that labeling will result
in an eventually crushing information load. The advocate points to the existence
of built-in checks which will prevent
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25such an eventuality. Labels by nature only go on the relevant product - meat,
fruit, etc, - not on all products. This in and of itself decreases the informa-
tion load presented. In addition, consumers are not so easily overwhelmed by
information as critics predict. Consumers don't conduct complex analyses on
every product each time they enter a store but rather evolve decision-making
eciencies { operating paradigms that guide their behavior. The availability
of labels can help to inform these operating paradigms by making information
available to consumers in their environment. Consumers wishing not to attend
to the information can easily tune it out. Making the information available to
the consumer when possible allows each consumer to be the judge as to what
matters to him or her. Lastly, if at some point in the future we are concerned
that labels have become too unruly and overwhelming, we could through reg-
ulation establish a means of priortization, privileging issues in which there is
a genuine scientic dispute and in which values are paramount. Wre far from
that situation today, however.
Fifth, the labeling advocate would argue that although a labeling system in
which a consumer pays a premium to minimize contribution to a societal risk
is somewhat unusual, there is some precedent for such a system and there is no
inherent reason that it is not defensible. Although many individuals purchase or-
ganic goods to minimize risks to their own health, some purchase organic goods
based on broad societal concerns such as the desire to minimize the deterimental
environmental impacts of pestidicide-dependent agricultural production. Fur-
ther, even if there were no such precedent, the fact that a benet is a dispersed
public benet rather than a concentrated individual benet does not appear
to be a valid moral basis for not allowing the choice. If a consumer desires to
pay more for meat in order to help to protect a societal good in an incremental
fashion along with other consumers, the consumer should have the option of
doing so.
To summarize, although it would be imperfect in many respects, a labeling
system which would provide consumers the option of purchasing meat produced
without subtherapeutic use of antibiotics could be a means of achieving in-
creased levels of liberty, eciency and democracy within the context of
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26a stalled public policy debate.
CONCLUSION
This paper has explored the clash of two dominant expert paradigms over the
use of subtherapeutic antibiotics in animal feed. Given the apparent insolubility
of this battle and the policy dominance of one side in the debate, a labeling
scheme is one potential means of allowing greater levels of expression and choice
in what is essentially a values-based debate.
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